SecBot SecBot
DEFA14A ·Filed May 28, 2026

CHRS

Coherus Oncology, Inc.
NEUTRAL
Impact 4/10
Horizonimmediate Processed5mo ago SEC0001104659-26-067154
Proxy solicitation materials
Actionable Insight • Neutral

The outcome is binary after the reconvened vote on May 29. Approval would reduce option strike prices to market, potentially dilutive if currently out-of-the-money options become exercisable, but also removes potential overhang of underwater options. Rejection leaves the current option structure unchanged. Monitor the May 29 closing price and the vote result for near-term impact.

DirectionNeutral
Confidencemedium
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.65
T+0 close · May 28, 2026 · via day close
Latest settled
−13.94%
T+60 · $1.42
Vs SPY
−15.67%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $1.65entry
  2. T+1 · 6mo ago −3.64%α −3.88% · $1.59
  3. T+5 · 6mo ago −4.55%α −4.86% · $1.58
  4. T+20 · 5mo ago −9.09%α −5.95% · $1.50
  5. T+60 · 3mo ago −13.94%α −15.67% · $1.42

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining votes on Proposal No. 4, a stock option repricing that would set the exercise price of certain outstanding options to the May 29 closing price and extend terms by 10 years. Approval requires a majority of votes cast (excluding abstentions and broker non-votes). Voting on the other four proposals was completed.

Key Financial Metrics

Meeting
2026-05-29

Key Facts

  • Annual meeting adjourned from May 27 to May 29, 2026 at 3:00 PM PT to finish counting votes on Proposal No. 4.
  • Proposal No. 4 would reprice eligible options to May 29 closing price and extend term 10 years from May 29, 2026.
  • If options are exercised or holder terminates service before May 29, 2027, the exercise price reverts to the original price.
  • Quorum was present; votes on Proposals 1, 2, 3, and 5 were completed at the original meeting.
  • Proposal No. 4 requires majority of votes cast for approval (abstentions and broker non-votes excluded).

Financial Impact

Stock option repricing to then-current closing price, dollar value depends on May 29 close and number of eligible options; no figures provided.

dilutioncompensation expense

Risk Factors

  • Approval could signal management retention but also implies shareholder willingness to reprice, may set precedent for future repricings.
  • No specific share counts or option details disclosed; materiality of repricing cannot be assessed from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-067154
Document: 0001104659-26-067154-index-headers.html0001104659-26-067154
Document: 0001104659-26-067154-index.html0001104659-26-067154
Document: 0001104659-26-067154.txt0001104659-26-067154

Track record

15 reports on CHRS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
  2. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
  3. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
  4. Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
  5. Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
  6. Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
  7. Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
  8. Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
  9. May 28, 202624w ago DEFA14A Neutral 4/10 Viewing Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
  10. May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026